MetaVia Inc. announced preclinical study results showing that their drug candidate DA-1726 is mainly absorbed and retained in fat tissues, supporting its once-weekly dosing for obesity treatment. The drug showed highest exposure in adipose tissue and prolonged retention, aligning with clinical findings of significant waist circumference reduction. DA-1726 acts as a dual agonist targeting GLP-1 and glucagon receptors to reduce appetite and increase energy use. MetaVia plans to report further clinical data by early 2027, reinforcing DA-1726's promise as a next-generation obesity therapy.
Intellia Therapeutics saw a boost after Wedbush analyst raised its price target to $13, signaling potential upside from its current $12.64 share price. The FDA granted Priority Review to Intellia's lonvo-z treatment for Hereditary Angioedema, with a ...
Signet Jewelers reported Q2 fiscal 2027 earnings of $2.19 per share, surpassing analyst estimates of $1.69 by nearly 30%, marking its sixth consecutive quarter of earnings beats. Although revenue slightly missed expectations at $1.528 billion versus ...
UBS increased its price target for ABM Industries to $51.50 following the company's strong quarterly earnings and revenue growth. ABM reported a 4.2% revenue increase to $2.32 billion and a 19% rise in net income to $49.7 million, alongside strong ca...
Chewy reported quarterly earnings of $0.36 per share, doubling analyst estimates of $0.18, with net income rising to $80.5 million from $62 million a year ago. Quarterly revenue reached $3.33 billion, slightly above expectations, marking a 7.3% incre...
AeroVironment, a leading drone maker, is set to report its Q3 earnings on September 9, 2026, with analysts expecting EPS between $0.22 and $0.25 and revenue near $452-$456 million. The company recently secured major contracts worth over $865 million ...
